Source: Annual Congress 2012 - Abestosis, silicosis and hypersensitivity pneumonitis
Disease area: Interstitial lung diseases, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Musk, P. Franklin, P. Aboagye-Sarfo, A. Reid, N. Olsen, L. Samuel, G. Berry, N. de Klerk (Perth, Australia). Exposure characteristics of patients with different pathological types of malignant mesothelioma. Eur Respir J 2012; 40: Suppl. 56, 4016

Member's Comments

No comment yet.

Related content which might interest you: Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 784s Year: 2006 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Clinical characteristics, treatment and survival outcomes in malignant mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Prognostic impact of histology and treatment modalities in malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009 Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 The importance of radiological findings to distinguish benign and malignant pleural diseases Source: Annual Congress 2008 - Imaging and measurement techniques in the evaluation of pulmonary embolism, COPD and pleural diseases Year: 2008 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Biological characteristics of dendritic cells from malignant pleural effusions in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 The analysis of clinicopathological characteristics and prognosis of malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2003; 22: Suppl. 45, 62s Year: 2003 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 BAP1 expression and treatment outcomes in malignant mesothelioma. Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017